Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Onychomycosis Pipeline Drugs Market Overview
Onychomycosis (Tinea Unguium) pipeline research report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects.
Key Targets in the Onychomycosis Pipeline Market
The key targets in the onychomycosis pipeline market are Squalene Monooxygenase, Cell Membrane, Lanosterol 14 Alpha Demethylase, Cell Wall, and Ergosterol. Squalene Monooxygenase has the highest number of pipeline products in the onychomycosis pipeline market.
Onychomycosis Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Onychomycosis Pipeline Market
The key MoA in the onychomycosis pipeline market are Squalene Monooxygenase Inhibitor, Cell Membrane Disruptor, Lanosterol 14 Alpha Demethylase Inhibitor, Cell Wall Disruptor, and Ergosterol Inhibitor. Squalene Monooxygenase Inhibitor has the highest number of pipeline products.
Onychomycosis Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Onychomycosis Pipeline Market
The key RoA in the onychomycosis pipeline market are topical, oral, cutaneous, intravenous, and nasal. Topical has the highest number of pipeline products in the onychomycosis pipeline market.
Onychomycosis Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Onychomycosis Pipeline Market
The key molecule types in the onychomycosis pipeline market are small molecule, biologic, peptide, and synthetic peptide. Small molecule has the highest number of pipeline products.
Onychomycosis Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the Onychomycosis Pipeline Market
The key companies in the onychomycosis pipeline market are Kaken Pharmaceutical Co Ltd, Blueberry Therapeutics Ltd, Moberg Pharma AB, Acea Biotech Inc, Almirall SA 1, Amtixbio Co Ltd, and ASCIL Biopharm. Kaken Pharmaceutical Co Ltd has the highest number of pipeline products.
Onychomycosis Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
| Key targets | Squalene Monooxygenase, Cell Membrane, Lanosterol 14 Alpha Demethylase, Cell Wall, and Ergosterol |
| Key MoA | Squalene Monooxygenase Inhibitor, Cell Membrane Disruptor, Lanosterol 14 Alpha Demethylase Inhibitor, Cell Wall Disruptor, and Ergosterol Inhibitor |
| Key RoA | Topical, Oral, Cutaneous, Intravenous, and Nasal |
| Key molecule types | Small Molecule, Biologic, Peptide, and Synthetic Peptide |
| Key companies | Kaken Pharmaceutical Co Ltd, Blueberry Therapeutics Ltd, Moberg Pharma AB, Acea Biotech Inc, Almirall SA 1, Amtixbio Co Ltd, and ASCIL Biopharm |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Almirall SA
Amtixbio Co Ltd
ASCIL Biopharm
Blueberry Therapeutics Ltd
CSA Biotechnologies LLC
DermBiont Inc
Exodos Life Sciences Limited Partnership
Hallux Inc
Hexima Ltd
Infextious Therapeutic
Kaken Pharmaceutical Co Ltd
Moberg Pharma AB
Mycovia Pharmaceuticals Inc
NAL Pharmaceuticals Ltd
Nektr Technologies Ltd
Novabiotics Ltd
Photonamic GmbH & Co KG
SaNOtize Research and Development Corp
TTY Biopharm Co Ltd
Turn Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the onychomycosis pipeline market?
The key targets in the onychomycosis pipeline market are Squalene Monooxygenase, Cell Membrane, Lanosterol 14 Alpha Demethylase, Cell Wall, and Ergosterol.
-
What are the key MoA in the onychomycosis pipeline market?
The key MoA in the onychomycosis pipeline market are Squalene Monooxygenase Inhibitor, Cell Membrane Disruptor, Lanosterol 14 Alpha Demethylase Inhibitor, Cell Wall Disruptor, and Ergosterol Inhibitor.
-
What are the key RoA in the onychomycosis pipeline market?
The key MoA in the onychomycosis pipeline market are topical, oral, cutaneous, intravenous, and nasal.
-
What are the key molecule types in the onychomycosis pipeline market?
The key molecule types in the onychomycosis pipeline market are small molecule, biologic, peptide, and synthetic peptide.
-
What are the key companies in the onychomycosis pipeline market?
The key companies in the onychomycosis pipeline market are Kaken Pharmaceutical Co Ltd, Blueberry Therapeutics Ltd, Moberg Pharma AB, Acea Biotech Inc, Almirall SA 1, Amtixbio Co Ltd, and ASCIL Biopharm.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Infectious Disease reports